Global Leading Market Research Publisher QYResearch announces the release of its latest report “Affinity Chromatography Purification of Proteins – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Affinity Chromatography Purification of Proteins market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Affinity Chromatography Purification of Proteins was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032.
Addressing Core Biopharmaceutical Purification, Monoclonal Antibody Isolation, and High-Purity Protein Production Pain Points
Biopharmaceutical manufacturers, drug discovery researchers, biomedical scientists, and clinical diagnostic labs face persistent challenges: producing high-purity therapeutic proteins (monoclonal antibodies (mAbs), Fc-fusion proteins, recombinant proteins) requires efficient, selective separation from complex cell lysates or culture media. Traditional chromatography methods (ion exchange, size exclusion) lack selectivity for target proteins, requiring multiple steps (low yield, high cost). Affinity chromatography purification of proteins—utilizing specific biological interactions (antigen-antibody, receptor-ligand, enzyme-substrate, metal chelation (His-tag))—has emerged as the gold standard for high-purity, single-step protein purification. However, product selection is complicated by two distinct affinity approaches: spontaneous affinity chromatography (natural biological interactions, e.g., Protein A/G for antibodies) versus artificial affinity chromatography (engineered tags (His-tag, GST, MBP, FLAG, Strep-tag) with corresponding resins). Over the past six months, new biosimilar approvals, monoclonal antibody production expansion, and gene therapy development have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5986211/affinity-chromatography-purification-of-proteins
Key Industry Keywords (Embedded Throughout)
- Affinity chromatography purification
- Spontaneous artificial affinity
- Monoclonal antibody purification
- Drug discovery biomedical
- Protein A His-tag
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global affinity chromatography purification of proteins market is concentrated among global life sciences and bioprocessing leaders. Key players include GE Healthcare Life Sciences (Cytiva, US/Sweden), Merck Millipore (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), Sino Biological (China), Sunresin (China), Tosoh Bioscience (Japan), Pall Corporation (US), Qiagen (Germany), Thermo Fisher Scientific (US), PerkinElmer (US), BioVision, Inc. (US), Navigo Proteins (Germany), and Zoonbio Biotechnology Co., Ltd (China).
Three recent developments are reshaping demand patterns:
- Monoclonal antibody (mAb) and biosimilar production: Global mAb market >$200B (2025), with biosimilar approvals increasing (Humira, Herceptin, Rituxan, Avastin). Protein A affinity chromatography (spontaneous affinity) is the standard capture step for mAb purification (high selectivity, >95% purity in single step). mAb segment grew 10-12% in 2025.
- Gene therapy and viral vector production: Adeno-associated virus (AAV), lentivirus, and other viral vectors for gene therapy require affinity purification (AVB Sepharose, heparin affinity). Gene therapy segment grew 15-18% in 2025.
- Fc-fusion proteins and bispecific antibodies: Novel modalities (Fc-fusion, bispecific, antibody-drug conjugates (ADCs)) require affinity chromatography (Protein A, Protein L, or custom affinity resins). Novel modality segment grew 12-15% in 2025.
Technical Deep-Dive: Spontaneous vs. Artificial Affinity Chromatography
- Spontaneous Affinity Chromatography (natural biological interactions). Advantages: high selectivity (Protein A/G for antibodies, lectin for glycoproteins, heparin for growth factors/coagulation factors), single-step purification (70-95% purity), and well-established platforms (mAb capture). A 2025 study from the International Bioprocessing Association found that Protein A affinity chromatography achieves >98% purity for mAbs in a single step. Disadvantages: resin cost (Protein A $5,000-15,000 per liter), limited to specific protein classes. Spontaneous accounts for approximately 55-60% of affinity chromatography purification market value (higher ASP), dominating mAb, Fc-fusion, and therapeutic protein production.
- Artificial Affinity Chromatography (engineered tags (His-tag, GST, MBP, FLAG, Strep-tag, HA-tag) with corresponding resins). Advantages: versatile (any recombinant protein with tag), lower resin cost ($500-2,000 per liter), and mild elution conditions (imidazole for His-tag, glutathione for GST). Disadvantages: tag removal may be required (protease cleavage), lower purity than Protein A (85-95%). Artificial accounts for approximately 40-45% of volume, dominating recombinant protein production (drug discovery, structural biology, biomedical research).
User case example: In November 2025, a biopharmaceutical CMO (contract manufacturing organization) published results from mAb purification (10,000 L bioreactor, 5 g/L titer) using Protein A affinity chromatography (Cytiva, Merck, Tosoh). The 12-month study (completed Q1 2026) showed:
- Purification step: Protein A affinity capture (spontaneous affinity).
- Purity: >98% (host cell protein (HCP) <100 ppm, DNA <10 pg/mg).
- Yield: 95% (10,000 L → 47.5 kg mAb).
- Resin cost: Protein A $10,000/L (50 cycles, $200/L per batch).
- Alternatives: ion exchange + hydrophobic interaction (4 steps, 70% yield, 95% purity).
- Decision: Protein A affinity for mAb capture; artificial affinity (His-tag) for recombinant protein production.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Affinity chromatography resin manufacturing (agarose or polymer bead functionalization (Protein A ligand (recombinant Protein A, alkali-stable variants), metal chelate (Ni-NTA, Co-TALON), glutathione, amylose, streptavidin)) follows batch chemical manufacturing (low volume, high value). Production volumes: tens of thousands of liters of resin annually.
- Pre-packed column manufacturing (resin packed into plastic or stainless steel columns) is batch discrete.
Exclusive observation: Based on analysis of early 2026 product launches, a new “continuous affinity chromatography” system (simulated moving bed (SMB), periodic counter-current chromatography (PCC)) is emerging for high-throughput bioprocessing (10,000+ L bioreactors). Traditional affinity chromatography is batch (bind-elute, cycle time 2-4 hours). Continuous systems increase resin utilization (30-50% less resin), reduce buffer consumption (40-60%), and enable continuous downstream processing. Cytiva (AKTA ready), Merck (Mobius), and Sartorius launched continuous affinity systems in Q1 2026. Continuous systems command 50-100% price premium ($500k-1M vs. $100k-300k for batch).
Application Segmentation: Drug Discovery, Biomedical Research, Clinical Diagnosis
- Drug Discovery (biopharmaceutical development, mAb discovery, Fc-fusion, bispecific, ADC, recombinant protein screening) accounts for 45-50% of affinity chromatography purification market value (largest segment). Artificial affinity (His-tag, GST) for discovery; spontaneous (Protein A) for development. Growing at 8-10% CAGR.
- Biomedical Research (academic labs, structural biology, protein-protein interactions, enzymology, signaling pathways) accounts for 30-35% of value. Artificial affinity (His-tag, GST, MBP, FLAG, Strep-tag) dominates. Growing at 5-7% CAGR.
- Clinical Diagnosis (diagnostic antibody production, antigen purification for immunoassays) accounts for 15-20% of value. Spontaneous affinity (Protein A/G) and artificial affinity. Growing at 6-8% CAGR.
Strategic Outlook & Recommendations
The global affinity chromatography purification of proteins market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Biopharmaceutical manufacturers: Protein A affinity chromatography (spontaneous) for mAb, Fc-fusion, bispecific capture step (high selectivity, single-step purity >95%). Continuous affinity chromatography for high-volume (>10,000 L) bioprocessing (reduced resin cost, buffer consumption). Artificial affinity (His-tag) for recombinant protein production.
- Drug discovery and biomedical researchers: Artificial affinity chromatography (His-tag, GST, MBP, FLAG, Strep-tag) for recombinant protein purification (versatile, lower cost). Pre-packed columns for convenience (spin columns, gravity columns, FPLC-compatible).
- Gene therapy manufacturers: Affinity chromatography (AVB Sepharose, heparin affinity) for AAV, lentivirus purification. Custom affinity resins for novel viral vectors.
- Manufacturers (Cytiva, Merck, Bio-Rad, Thermo Fisher, Tosoh, Pall, Qiagen, Sino Biological, Sunresin, Navigo Proteins): Invest in continuous affinity chromatography systems (high-volume bioprocessing), alkali-stable Protein A variants (in-place cleaning (CIP) compatibility, longer resin life), and custom affinity resins (novel targets, bispecific antibodies). Pre-packed, ready-to-use columns for research and process development.
For high-purity therapeutic protein production (mAbs, Fc-fusion, bispecifics) and recombinant protein purification, affinity chromatography is the gold standard. Spontaneous affinity (Protein A/G) dominates mAb capture (single-step >95% purity). Artificial affinity (His-tag, GST) dominates research and recombinant protein production. Continuous affinity chromatography emerging for high-volume bioprocessing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
